Topical Methotrexate and CO2 Laser for Non-Segmental Vitiligo

This clinical trial explores the effectiveness of using a combination of fractional CO2 laser and topical methotrexate gel compared to using the gel alone in treating non-segmental vitiligo. The study involves adult participants aged 18-65 who have stable vitiligo with similar skin lesions on both sides of the body. This research aims to determine whether the addition of laser treatment can enhance repigmentation of the skin, providing new insights for individuals who haven’t responded to recent corticosteroid or phototherapy treatments. Such findings could lead to improved treatment options for those affected by vitiligo, potentially enhancing their quality of life. Participants in the study will have one side of their body treated with both the fractional CO2 laser and methotrexate gel, while the other side will receive only the gel, with the assignment being random to ensure unbiased results. The laser treatment is conducted in four sessions spaced three weeks apart. Throughout the six-month study, participants will undergo regular assessments including digital photography to measure skin repigmentation, safety checks, and surveys on patient satisfaction. The main goal is to see how much the skin repigments with the different treatments, while also monitoring any side effects and overall satisfaction with the treatment.